A new NIMH grant is enabling scientists to begin testing safety and effectiveness of potential medications for fragile-X syndrome, the most common inherited form of mental retardation.
A new NIMH grant is enabling scientists to begin testing safety and effectiveness of potential medications for fragile-X syndrome, the most common inherited form of mental retardation.